NewsMeter
The Nasdaq Listing Qualifications Department has determined that Moleculin Biotech, Inc. (MBRX) is ineligible for a compliance period to regain its minimum bid price status.
The ruling was issued on September 15, 2026, following a review of the company's trading performance over the prior 30 consecutive business days.
This decision strips the Houston-based biotech of the standard 180-calendar day window typically afforded to firms that fail to meet Nasdaq Listing Rule 5550(a)(2).
The math behind the disqualification is specific: the staff found that the closing bid price of MBRX common stock, par value $0.001 per share, remained below $1.00 per share from July 31, 2026, through September 11, 2026.
Keep reading